LGND RSI Chart
Last 7 days
-1.4%
Last 30 days
9.1%
Last 90 days
16.8%
Trailing 12 Months
11.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 118.3M | 0 | 0 | 0 |
2023 | 203.7M | 179.9M | 153.6M | 131.3M |
2022 | 231.5M | 202.7M | 202.3M | 196.2M |
2021 | 199.8M | 237.3M | 255.1M | 241.5M |
2020 | 110.0M | 126.4M | 143.4M | 186.4M |
2019 | 238.8M | 173.7M | 152.9M | 120.3M |
2018 | 251.5M | 251.5M | 251.5M | 251.5M |
2017 | 135.5M | 206.0M | 230.0M | 251.5M |
2016 | 87.0M | 88.1M | 92.0M | 109.0M |
2015 | 63.2M | 71.0M | 73.7M | 71.9M |
2014 | 53.3M | 54.3M | 56.3M | 64.5M |
2013 | 37.4M | 41.2M | 47.9M | 49.0M |
2012 | 31.8M | 30.1M | 30.7M | 31.4M |
2011 | 21.5M | 23.1M | 21.0M | 30.0M |
2010 | 0 | 33.8M | 28.7M | 23.5M |
2009 | 0 | 0 | 0 | 38.9M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 30, 2024 | aryeh jason | acquired | 125,834 | 52.3 | 2,406 | - |
Apr 24, 2024 | kozarich john w | acquired | 113,840 | 39.35 | 2,893 | - |
Mar 25, 2024 | davis todd c | acquired | 919,147 | 57.3929 | 16,015 | chief executive officer |
Mar 05, 2024 | aryeh jason | acquired | 113,840 | 39.35 | 2,893 | - |
Mar 05, 2024 | sabba stephen l | acquired | - | - | 2,893 | - |
Mar 05, 2024 | sabba stephen l | sold | -140,650 | 74.3 | -1,893 | - |
Feb 28, 2024 | espinoza octavio | sold | -12,384 | 88.46 | -140 | chief financial officer |
Feb 28, 2024 | espinoza octavio | acquired | 71,564 | 56.6173 | 1,264 | chief financial officer |
Feb 27, 2024 | davis todd c | acquired | - | - | 32,436 | chief executive officer |
Feb 27, 2024 | reardon andrew | acquired | - | - | 7,208 | chief legal officer & |
Which funds bought or sold LGND recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CASTLEARK MANAGEMENT LLC | reduced | -1.26 | 47,663 | 4,525,840 | 0.19% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 437 | 1,136,280 | 1,388,680 | -% |
May 16, 2024 | Ancora Advisors LLC | sold off | -100 | -54.00 | - | -% |
May 16, 2024 | COMERICA BANK | reduced | -8.62 | -39,696 | 573,212 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -5.26 | -37,900 | 1,213,020 | -% |
May 15, 2024 | CAPTRUST FINANCIAL ADVISORS | added | 6.37 | 39,996 | 491,013 | -% |
May 15, 2024 | TWO SIGMA ADVISERS, LP | reduced | -20.37 | -71,338 | 314,330 | -% |
May 15, 2024 | AQR CAPITAL MANAGEMENT LLC | reduced | -57.53 | -2,170,930 | 1,623,330 | -% |
May 15, 2024 | BARCLAYS PLC | reduced | -44.39 | -1,039,000 | 1,374,000 | -% |
May 15, 2024 | Aquatic Capital Management LLC | new | - | 365,500 | 365,500 | 0.01% |
Unveiling Ligand Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Ligand Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Ligand Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 10.2% | 31.00 | 28.00 | 33.00 | 26.00 | 44.00 | 50.00 | 59.00 | 50.00 | 37.00 | 56.00 | 60.00 | 79.00 | 47.00 | 70.00 | 42.00 | 41.00 | 33.00 | 27.00 | 25.00 | 25.00 | 43.00 |
Operating Expenses | -11.0% | 28.00 | 31.00 | 32.00 | 28.00 | 30.00 | 70.00 | 47.00 | 41.00 | 34.00 | 41.00 | 35.00 | 25.00 | 37.00 | 76.00 | 38.00 | 34.00 | 29.00 | 37.00 | 30.00 | 29.00 | 30.00 |
S&GA Expenses | -100.0% | - | 16.00 | 15.00 | 11.00 | 11.00 | 31.00 | 15.00 | 12.00 | 12.00 | 13.00 | 11.00 | 12.00 | 11.00 | 26.00 | 15.00 | 10.00 | 9.00 | 10.00 | 10.00 | 11.00 | 11.00 |
R&D Expenses | 8.8% | 6.00 | 5.00 | 6.00 | 7.00 | 7.00 | 9.00 | 9.00 | 8.00 | 9.00 | 8.00 | 7.00 | 7.00 | 9.00 | 3.00 | 13.00 | 13.00 | 12.00 | 19.00 | 14.00 | 12.00 | 11.00 |
EBITDA Margin | 73.8% | 1.33* | 0.77* | 0.72* | 0.78* | 0.73* | 0.46* | 0.44* | 0.47* | 0.54* | 0.59* | 0.56* | 0.46* | - | - | - | - | - | - | - | - | - |
Interest Expenses | 7.6% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 4.00 | 4.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 |
Income Taxes | 2603.0% | 27.00 | -1.09 | -1.87 | 1.00 | 12.00 | 39.00 | 3.00 | -3.94 | 4.00 | 4.00 | 2.00 | 3.00 | -12.34 | -2.39 | -4.91 | 6.00 | -6.28 | -0.81 | -4.62 | -3.61 | 176 |
Earnings Before Taxes | 563.5% | 113 | 17.00 | -12.14 | 3.00 | 56.00 | 24.00 | 12.00 | 9.00 | -9.14 | 18.00 | 15.00 | 33.00 | 6.00 | 15.00 | -11.61 | 28.00 | -30.41 | -8.18 | -19.87 | -18.03 | 843 |
EBT Margin | 112.0% | 1.03* | 0.48* | 0.46* | 0.53* | 0.49* | 0.18* | 0.15* | 0.16* | 0.25* | 0.30* | 0.27* | 0.18* | - | - | - | - | - | - | - | - | - |
Net Income | 373.6% | 86.00 | 18.00 | -10.27 | 2.00 | 42.00 | -17.48 | 0.00 | -0.89 | -15.38 | -5.42 | 14.00 | 31.00 | 18.00 | 6.00 | -6.70 | 22.00 | -24.13 | -7.36 | -15.25 | -14.42 | 666 |
Net Income Margin | 105.0% | 0.81* | 0.40* | 0.11* | 0.15* | 0.12* | -0.17* | -0.11* | -0.04* | 0.10* | 0.24* | 0.27* | 0.20* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 143.6% | 19.00 | 8.00 | 7.00 | -0.28 | 32.00 | 51.00 | 16.00 | 5.00 | 47.00 | 25.00 | 18.00 | 19.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 16.1% | 914 | 787 | 769 | 758 | 811 | 763 | 1,051 | 1,076 | 1,105 | 1,298 | 1,274 | 1,256 | 1,295 | 1,362 | 1,247 | 1,243 | 1,186 | 1,495 | 1,547 | 1,802 | 1,914 |
Current Assets | 55.4% | 369 | 237 | 254 | 277 | 328 | 264 | 220 | 244 | 276 | 465 | 432 | 411 | 437 | 501 | 858 | 864 | 831 | 1,124 | 1,183 | 1,442 | 1,568 |
Cash Equivalents | 118.2% | 50.00 | 23.00 | 19.00 | 28.00 | 89.00 | 45.00 | 4.00 | 5.00 | 15.00 | 20.00 | 23.00 | 22.00 | 32.00 | 48.00 | 457 | 116 | 118 | 72.00 | 226 | 274 | 107 |
Inventory | -11.0% | 21.00 | 24.00 | 25.00 | 27.00 | 14.00 | 13.00 | 22.00 | 25.00 | 26.00 | 27.00 | 33.00 | 40.00 | 37.00 | 26.00 | 13.00 | 4.00 | 7.00 | 7.00 | 7.00 | 10.00 | 12.00 |
Net PPE | -3.0% | 15.00 | 16.00 | 16.00 | 11.00 | 12.00 | 12.00 | 33.00 | 31.00 | 25.00 | 13.00 | 19.00 | 18.00 | 17.00 | 13.00 | 7.00 | 8.00 | 7.00 | 7.00 | 6.00 | 6.00 | 6.00 |
Goodwill | 1.8% | 105 | 103 | 2.00 | 106 | 106 | 106 | - | 181 | 181 | - | 190 | 191 | 191 | 190 | 82.00 | 103 | 9.00 | 95.00 | 94.00 | 88.00 | 87.00 |
Liabilities | 24.4% | 107 | 86.00 | 101 | 93.00 | 165 | 165 | 234 | 274 | 312 | 476 | 462 | 470 | 549 | 653 | 550 | 548 | 524 | 728 | 697 | 760 | 834 |
Current Liabilities | 6.2% | 18.00 | 17.00 | 16.00 | 29.00 | 99.00 | 99.00 | 135 | 168 | 43.00 | 42.00 | 36.00 | 52.00 | 96.00 | 100 | 42.00 | 29.00 | 20.00 | 17.00 | 36.00 | 109 | 187 |
Long Term Debt | - | - | - | - | - | - | - | - | - | 177 | 321 | 317 | 315 | 352 | 442 | 455 | 450 | 444 | 639 | 632 | 624 | 617 |
LT Debt, Current | - | - | - | - | - | 77.00 | 77.00 | 77.00 | 115 | - | - | - | - | - | - | - | - | - | - | - | 27.00 | 27.00 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | 177 | 321 | 317 | 315 | 352 | 442 | 455 | 450 | 444 | 639 | 632 | 624 | 617 |
Shareholder's Equity | 15.1% | 807 | 701 | 668 | 665 | 646 | 597 | 816 | 802 | 793 | 821 | 812 | 787 | 746 | 710 | 698 | 695 | 662 | 767 | 851 | 1,041 | 1,080 |
Retained Earnings | 17.1% | 589 | 503 | 485 | 495 | 493 | 451 | 468 | 468 | 469 | 449 | 455 | 441 | 410 | 392 | 386 | 393 | 371 | 400 | 407 | 423 | 437 |
Additional Paid-In Capital | 9.8% | 218 | 199 | 184 | 171 | 154 | 148 | 349 | 335 | 325 | 373 | 358 | 347 | 337 | 318 | 313 | 304 | 296 | 367 | 445 | 619 | 643 |
Shares Outstanding | 2.1% | 18.00 | 18.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 900 | - | - | - | 1,000 | - | - | - | 1,800 | - | - | - | 1,200 | - | - | - | 1,800 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 132.3% | 18,732 | 8,065 | 7,646 | -82.00 | 33,948 | 53,472 | 20,489 | 11,878 | 52,011 | 27,642 | 20,025 | 20,377 | 10,754 | 537 | 12,745 | 24,382 | 16,922 | -7,339 | -6,197 | -61,058 | 45,258 |
Share Based Compensation | 28.2% | 7,334 | 5,721 | 6,884 | 7,207 | 5,931 | 29,145 | 12,597 | 9,499 | 9,044 | 10,408 | 9,754 | 10,216 | 8,405 | 9,975 | 7,740 | 7,359 | 5,653 | 6,300 | 6,297 | 6,571 | 5,347 |
Cashflow From Investing | 63.3% | -3,775 | -10,284 | -19,503 | 7,556 | 10,549 | -7,284 | 19,176 | 37,851 | 113,881 | -35,713 | -18,217 | 19,338 | 65,115 | -382,202 | 332,071 | -26,757 | 308,536 | -63,179 | 169,517 | 265,803 | 94,777 |
Cashflow From Financing | 129.2% | 12,182 | 5,315 | 3,270 | -67,757 | -775 | -5,298 | -40,829 | -59,442 | -170,421 | 4,164 | -385 | -49,905 | -91,635 | -27,529 | -3,706 | -5.00 | -279,305 | -83,693 | -211,312 | -37,591 | -152,576 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4,711 | - | - | 73,287 | 84,250 | 181,188 | 33,717 | 151,585 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues and other income: | ||
Total revenues and other income | $ 30,978 | $ 43,979 |
Operating costs and expenses: | ||
Cost of Captisol | 2,882 | 3,717 |
Amortization of intangibles | 8,186 | 8,539 |
Research and development | 5,971 | 6,663 |
General and administrative | 10,951 | 10,855 |
Total operating costs and expenses | 27,990 | 29,774 |
Operating income from continuing operations | 2,988 | 14,205 |
Non-operating income and expenses: | ||
Gain from short-term investments | 110,772 | 39,533 |
Interest income | 2,020 | 1,435 |
Interest expense | (141) | (240) |
Gain on derivative instruments | 196 | 0 |
Other non-operating income (expense), net | (2,388) | 603 |
Total non-operating income and expenses, net | 110,459 | 41,331 |
Income before income taxes from continuing operations | 113,447 | 55,536 |
Income tax expense | (27,308) | (11,922) |
Net income from continuing operations | 86,139 | 43,614 |
Net loss from discontinued operations | 0 | (1,665) |
Net income | $ 86,139 | $ 41,949 |
Earnings per share | ||
Basic net income from continuing operations per share (in USD per share) | $ 4.86 | $ 2.56 |
Basic net loss from discontinued operations per share (in USD per share) | 0 | (0.10) |
Basic net income per share (in USD per share) | $ 4.86 | $ 2.46 |
Shares used in basic per share calculation (in shares) | 17,732 | 17,063 |
Diluted net income from continuing operations per share (in USD per share) | $ 4.75 | $ 2.43 |
Diluted net loss from discontinued operations per share (in USD per share) | 0 | (0.09) |
Diluted net income per share (in USD per share) | $ 4.75 | $ 2.33 |
Shares used in diluted per share calculation (in shares) | 18,122 | 17,974 |
Royalties | ||
Revenues and other income: | ||
Total revenues and other income | $ 19,095 | $ 17,647 |
Revenue from intangible royalty assets | ||
Revenues and other income: | ||
Total revenues and other income | 18,357 | 17,154 |
Income from financial royalty assets | ||
Revenues and other income: | ||
Total revenues and other income | 738 | 493 |
Captisol | ||
Revenues and other income: | ||
Total revenues and other income | 9,212 | 10,622 |
Contract revenue and other income | ||
Revenues and other income: | ||
Total revenues and other income | $ 2,671 | $ 15,710 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 50,093 | $ 22,954 |
Short-term investments | 260,500 | 147,355 |
Accounts receivable, net | 28,435 | 32,917 |
Inventory | 21,337 | 23,969 |
Income taxes receivable | 0 | 6,395 |
Prepaid expenses | 1,237 | 1,182 |
Other current assets | 7,311 | 2,657 |
Total current assets | 368,913 | 237,429 |
Deferred income taxes, net | 0 | 214 |
Intangible assets, net | 291,420 | 299,606 |
Goodwill | 105,250 | 103,370 |
Long-term portion of financial royalty assets, net | 65,710 | 62,291 |
Property and equipment, net | 15,135 | 15,607 |
Operating lease right-of-use assets | 6,028 | 6,062 |
Finance lease right-of-use assets | 3,219 | 3,393 |
Equity method investment in Primrose Bio | 10,469 | 12,595 |
Other investments | 36,500 | 36,726 |
Other assets | 11,225 | 9,923 |
Total assets | 913,869 | 787,216 |
Current liabilities: | ||
Accounts payable | 1,893 | 2,427 |
Accrued liabilities | 12,430 | 12,467 |
Income taxes payable | 1,138 | 0 |
Deferred revenue | 1,227 | 1,222 |
Current contingent liabilities | 127 | 256 |
Current operating lease liabilities | 1,000 | 403 |
Current finance lease liabilities | 3 | 7 |
Total current liabilities | 17,818 | 16,782 |
Long-term deferred revenue | 3,065 | 1,444 |
Long-term contingent liabilities | 2,888 | 2,942 |
Deferred income taxes, net | 50,606 | 31,622 |
Long-term operating lease liabilities | 5,191 | 5,755 |
Other long-term liabilities | 27,780 | 27,758 |
Total liabilities | 107,348 | 86,303 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 60,000 shares authorized; 17,924 and 17,556 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 18 | 18 |
Additional paid-in capital | 218,258 | 198,696 |
Accumulated other comprehensive loss | (910) | (817) |
Retained earnings | 589,155 | 503,016 |
Total stockholders' equity | 806,521 | 700,913 |
Total liabilities and stockholders' equity | $ 913,869 | $ 787,216 |